Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 13/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320849 | 1.00 | CA1 (0.47) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL4382302 | 0.95 | CA1 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL10431195 | 0.93 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL86310 | 0.89 | CA1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL1654201 | 0.89 | CA1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL86237 | 0.89 | CA1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL30803584 | 0.86 | CA1 (0.42) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL4917594 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL24687980 | 0.84 | TDP1 (0.50) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL12734600 | 0.84 | CTSK (0.61) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CA1 4498/4885CA2 3900/4885CA7 193/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CA1 4498/4885CA2 3900/4885CA7 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.